Use of QRX-3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Ebima Clifford Okundaye

Status and phase: Not yet enrolling; Phase 3; Phase 2

Conditions: Acute Renal Failure (ARF); Acute Tubular Necrosis

Treatments: Drug: QRX-3

Study type: Interventional

Funder types: Industry

Identifiers

NCT07161843

0002

Details and patient eligibility

About

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Enrollment: 500 estimated patients

Sex: All

Ages: 10 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized patients
• presence of Acute renal failure
• Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of >2%
• willingness to participate

Exclusion criteria

High risk of bleeding Absence of hydronephrosis or obstructive uropathy Absence of baseline dialysis use single kidney status

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

500 participants in 2 patient groups, including a placebo group

Use of QRX-3 in addition to standard therapy

Experimental group

Description:

QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days

Treatment:

Drug: QRX-3

control group

Placebo Comparator group

Description:

placebo twice daily will be given to this group in addition to standard therapy

Treatment:

Drug: QRX-3